4.85
0.62%
0.03
시간 외 거래:
4.86
0.01
+0.21%
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
Vanda’s VGT-1849A gets orphan designation for polycythemia vera - BioWorld Online
HC Wainwright Reiterates Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity - Seeking Alpha
Vanda Pharmaceuticals Gets FDA Orphan-Drug Designation for Cancer Treatment - MarketWatch
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
Vanda Pharmaceuticals Secures FDA Orphan Drug Status for Novel Blood Cancer Treatment VGT-1849A - StockTitan
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com - MarketBeat
FDA's Gastro Drug Fast-Track Denial Survives DC Circ. - Law360
US Penny Stocks To Watch In December 2024 - Simply Wall St
DC Circuit Affirms FDA's Fast-Track Denial of Vanda Stomach Drug - Bloomberg Law
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc. - Marketscreener.com
Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com
Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat
Vanda Expands Efforts to Pull Two Hetlioz Copies From US Shelves - Bloomberg Law
Vanda Pharmaceuticals (STU:VM4) EV-to-Revenue : -0.37 (As of Dec. 01, 2024) - GuruFocus.com
Massachusetts Financial Services Co. MA Purchases New Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Long Term Trading Analysis for (VNDA) - Stock Traders Daily
Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com Canada
Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India
New Strong Buy Stocks For November 14th - Barchart
Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan
BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India
Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Inc (VNDA) Quarterly 10-Q Report - Quartz
Vanda Seeks New Markets for Hetlioz Amid Generic Competition - Sleep Review
Vanda: Q3 Earnings Snapshot - Middletown Press
Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... - Yahoo Finance
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results - PR Newswire
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
자본화:
|
볼륨(24시간):